South Australian Startup Splose Raises $46 Million in Another Series A
•February 8, 2026
0
Companies Mentioned
Why It Matters
The sizable round validates vertical SaaS and AI adoption in allied health, positioning Splose to challenge entrenched global practice‑management incumbents and accelerate international market penetration.
Key Takeaways
- •$46M Series A led by Spectrum Equity.
- •20,000+ practitioners using platform in Australia, NZ, UK.
- •AI tools produce 200,000 outcomes each month.
- •UK market growth exceeds 300% since entry.
- •Capital will fuel AI development and UK expansion.
Pulse Analysis
Splose’s $46 million Series A underscores the growing appetite for niche, cloud‑based solutions that address specific professional workflows. In a market traditionally dominated by broad‑stroke practice‑management suites, the Adelaide startup’s vertical focus on physiotherapists, occupational therapists and speech pathologists offers a differentiated value proposition. The backing from Spectrum Equity, a firm with a track record in vertical software, signals confidence that specialized platforms can achieve scale and attract substantial capital, even from outside Australia’s major tech hubs.
The integration of AI into Splose’s platform marks a pivotal shift for allied health practitioners seeking efficiency gains. Features such as automated transcription, note‑taking and AI‑assisted query handling claim to cut documentation time by up to 75%, translating into more face‑to‑face care. As competitors embed similar capabilities, Splose’s early mover advantage and community‑driven development could cement its reputation as a “loved” tool, a key metric for investors targeting sticky, high‑engagement user bases. The reported 200,000 monthly AI outcomes illustrate tangible adoption and set a benchmark for productivity improvements across the sector.
Internationally, Splose’s aggressive push into the United Kingdom leverages the country’s stringent compliance landscape, where legacy systems often falter. The 300% growth rate since its UK launch demonstrates strong market demand for compliant, AI‑enhanced solutions. With the fresh capital earmarked for deeper AI integration and regional expansion, Splose is poised to capture a larger share of the global practice‑management market, potentially influencing pricing dynamics and prompting incumbents to accelerate their own AI roadmaps. This expansion could also catalyze further investment into Australian SaaS firms targeting overseas verticals.
South Australian startup Splose raises $46 million in another Series A
Adelaide-based allied health software platform Splose has raised a $46 million Series A, with the company claiming it’s the largest ground ever secured by a South Australian SaaS business.
The round was led by US growth equity firm Spectrum Equity, with participation from sports‑star collective Athletic Ventures.
The company declined to disclose its latest valuation, though reports suggest it is comfortably above $100 million.
Splose was founded in 2016 by CEO Nicholas Sanderson. The company previously announced a $1.5 million Series A in November 2023, following on from $1 million raised in August 2022. Sydney‑based fund EVP also led a $5 million round 12 months ago.
Splose is an all‑in‑one platform for physiotherapists, occupational therapists, speech pathologists and other allied health professionals to manage appointments, client onboarding, invoicing and compliance.
The company says its software is now used by more than 20,000 individual allied health practitioners across Australia, New Zealand and the UK, doubling in 12 months.
Sanderson said several factors drove the leap to a much larger funding round, including rapid traction in the UK and the launch of new AI capabilities.
“We launched Splose AI in late 2024 and have been adding new features regularly ever since based on the feedback of our users,” he said.
“We launched into the UK market 18 months ago and have seen 300 % plus growth there. The UK market has considerable legislative and compliance frameworks, which means legacy software is even more embedded.”
AI now central
Splose has increasingly positioned itself as an AI‑powered platform for allied health, offering tools such as transcription, automated note‑taking, reporting and workflow automation.
Sanderson said the company is currently seeing more than 200,000 “AI outcomes” per month, including transcribed client notes and AI‑assisted queries.
“Our AI scribe helps practitioners focus on being present with clients, both transcribing sessions and allowing practitioners to dictate, then summarising these transcripts into draft‑ready notes for final editing and approval,” he said.
“Ask AI can summarise previous session notes, pull together client history and summarise client documents. Doctor referral letters can be drafted effortlessly with a prompt, bringing all the clinically relevant information into a letter ready to send to general practitioners.”
Splose claims its tools allow practitioners to transcribe notes four times faster than manual processes.
Practice management software is a competitive global category, with many large incumbents now adding AI features of their own.
Sanderson argued Splose’s advantage lies in its deep integration and community‑led product development.
UK plans
Sanderson declined to comment on how close the company is to profitability, saying the focus remains on building the best possible solution for allied health.
Splose did say the fresh capital will be used to accelerate product development, expand further into the UK and deepen the integration of artificial‑intelligence tools across its practice‑management platform.
“We’re accelerating product development to continue focusing on building deep integrated AI workflows that help practitioners save significant time in providing care and running their practice,” Sanderson said.
Spectrum Equity managing director Matt Neidlinger, who will join Splose’s board, said the firm was drawn to the company’s traction in a specific vertical.
“We seek to invest in vertical software businesses that deliver distinctive value and are truly loved by their users,” Neidlinger said.
South Australian Trade and Investment Minister Joe Szakacs congratulated the company on the milestone, noting it had previously received a $100,000 Seed Start grant from the state government.
Additional reporting by Simon Thomsen
This story first appeared on SmartCompany.
0
Comments
Want to join the conversation?
Loading comments...